JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB36385

Anti-C3a / C3a des Arg antibody [K13/16]

Be the first to review this product! Submit a review

|

(9 Publications)

Mouse Monoclonal C3 antibody. Suitable for IHC-P and reacts with Human samples. Cited in 9 publications.

View Alternative Names

CPAMD1, C3, Complement C3, C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1

4 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-C3a / C3a des Arg antibody [K13/16] (AB36385)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-C3a / C3a des Arg antibody [K13/16] (AB36385)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human liver tissue labelling C3a / C3a des Arg with ab36385 at a dilution of 1/150. Strong staining is visible in the veins.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-C3a / C3a des Arg antibody [K13/16] (AB36385)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-C3a / C3a des Arg antibody [K13/16] (AB36385)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human kidney tissue labelling C3a / C3a des Arg with ab36385 at a dilution of 1/75. Strong staining is visible in the of veins of nephritis.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-C3a / C3a des Arg antibody [K13/16] (AB36385)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-C3a / C3a des Arg antibody [K13/16] (AB36385)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human tonsil tissue labelling C3a / C3a des Arg with ab36385 at a dilution of 1/150. Strong staining is visible in the lumen of veins.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-C3a / C3a des Arg antibody [K13/16] (AB36385)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-C3a / C3a des Arg antibody [K13/16] (AB36385)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human kidney tissue labelling C3a / C3a des Arg with ab36385 at a dilution of 1/150. Strong staining is visible in the of veins of nephritis.

Key facts

Host species

Mouse

Clonality

Monoclonal

Clone number

K13/16

Isotype

IgG1

Light chain type

kappa

Carrier free

No

Reacts with

Human

Applications

IHC-P

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Epitope

Recognizes an epitope present on human C3, C3a and C3a(desArg).

Specificity

Does not cross react with C4a or C5a.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/150", "IHCP-species-notes": "<p></p>" } } }

Product details

Effectively inhibits the biological activity of C3a in a guinea-pig platelet activation assay.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.4
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

C3a also known as C3a des Arg or C3a full form is a small peptide anaphylatoxin derived from the complement component C3. It plays an important mechanical role in the immune system by acting as a potent mediator of inflammation. C3a weighs approximately 9 kDa. It expresses primarily on the surface of immune cells such as mast cells and basophils. The function of C3a involves the binding to the C3a receptor (C3aR) triggering a series of immune responses.
Biological function summary

C3a serves as an essential inflammatory agent and is part of the complement system an important component of the innate immune response. It contributes to the defense against pathogens by promoting chemotaxis degranulation and the release of histamine. C3a desArg a derivative of C3a generated by the removal of the C-terminal arginine residue has reduced inflammatory activity. The activity of C3a and its link to inflammation highlights its importance in maintaining immune homeostasis and responding to infectious threats.

Pathways

C3a plays an important role in the complement activation cascade particularly the classical and alternative pathways. This involvement highlights its relationship with proteins such as C3b and C5 which are critical in the opsonization and membrane attack complex formation. C3a's role in these pathways accentuates its importance in modulating inflammation and immune response.

Abnormalities in C3a regulation have notable implications. C3a is associated with various inflammatory and autoimmune diseases like asthma and rheumatoid arthritis. In asthma C3a interacts with other complement proteins such as C5a to exacerbate inflammation in the airways. Dysregulation of C3a and its conversion to C3a desArg may further contribute to pathologies implicating its potential as a therapeutic target in managing inflammatory diseases.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Precursor of non-enzymatic components of the classical, alternative, lectin and GZMK complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system.. Complement C3b. Non-enzymatic component of C5 convertase (PubMed : 28264884, PubMed : 31507604, PubMed : 3653927, PubMed : 3897448). Generated following cleavage by C3 convertase, it covalently attaches to the surface of pathogens, where it acts as an opsonin that marks the surface of antigens for removal (PubMed : 28264884, PubMed : 31507604, PubMed : 3653927, PubMed : 3897448, PubMed : 833545, PubMed : 8349625). Complement C3b binds covalently via its reactive thioester, to cell surface carbohydrates or immune aggregates (PubMed : 6903192). Together with complement C4b, it then recruits the serine protease complement C2b to form the C5 convertase, which cleaves and activate C5, the next component of the complement pathways (PubMed : 12878586, PubMed : 18204047, PubMed : 2387864). In the alternative complement pathway, recruits the serine protease CFB to form the C5 convertase that cleaves and activates C5 (PubMed : 624565, PubMed : 6554279).. C3a anaphylatoxin. Mediator of local inflammatory process released following cleavage by C3 convertase (PubMed : 6968751, PubMed : 37169960, PubMed : 37852260). Acts by binding to its receptor, C3AR1, activating G protein-coupled receptor signaling, promoting the phosphorylation, ARRB2-mediated internalization and endocytosis of C3AR1 (PubMed : 8702752, PubMed : 37169960, PubMed : 37852260). C3a anaphylatoxin stimulates the activation of immune cells such as mast cells and basophilic leukocytes to release inflammation agents, such as cytokines, chemokines and histamine, which promote inflammation development (PubMed : 23383423). Also acts as potent chemoattractant for the migration of macrophages and neutrophils to the inflamed tissues, resulting in neutralization of the inflammatory triggers by multiple ways, such as phagocytosis and generation of reactive oxidants (PubMed : 23383423, PubMed : 342601, PubMed : 5778786).. Acylation stimulating protein. Adipogenic hormone that stimulates triglyceride synthesis and glucose transport in adipocytes, regulating fat storage and playing a role in postprandial triglyceride clearance (PubMed : 10432298, PubMed : 15833747, PubMed : 16333141, PubMed : 19615750, PubMed : 2909530, PubMed : 8376604, PubMed : 9059512). Appears to stimulate triglyceride synthesis via activation of the PLC, MAPK and AKT signaling pathways (PubMed : 16333141). Acts by binding to its receptor, C5AR2, activating G protein-coupled receptor signaling, promoting the phosphorylation, ARRB2-mediated internalization and endocytosis of C5AR2 (PubMed : 11773063, PubMed : 12540846, PubMed : 19615750). In contrast to C3a anaphylatoxin peptide, does not show pro-inflammatory activity (PubMed : 37852260).. C3-beta-c. Acts as a chemoattractant for neutrophils in chronic inflammation.
See full target information C3

Publications (9)

Recent publications for all applications. Explore the full list and refine your search

Cells 14: PubMed40072066

2025

Finerenone Alleviates Over-Activation of Complement C5a-C5aR1 Axis of Macrophages by Regulating G Protein Subunit Alpha i2 to Improve Diabetic Nephropathy.

Applications

Unspecified application

Species

Unspecified reactive species

Zi-Han Li,Zi-Jun Sun,Sydney C W Tang,Ming-Hui Zhao,Min Chen,Dong-Yuan Chang

Computational and structural biotechnology journal 23:3634-3650 PubMed39469671

2024

The complement C3a/C3aR pathway is associated with treatment resistance to gemcitabine-based neoadjuvant therapy in pancreatic cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Saimeng Shi,Longyun Ye,Kaizhou Jin,Xianjun Yu,Duancheng Guo,Weiding Wu

Clinical and experimental medicine 24:139 PubMed38951265

2024

Complement C3a/C3aR and C5a/C5aR deposits accelerate the progression of advanced IgA nephropathy to end-stage renal disease.

Applications

Unspecified application

Species

Unspecified reactive species

Ying Wang,Shunlai Shang,Shimin Jiang,Guming Zou,Hongmei Gao,Wenge Li

JCI insight 7: PubMed36546481

2022

Deficiency of CFB attenuates renal tubulointerstitial damage by inhibiting ceramide synthesis in diabetic kidney disease.

Applications

Unspecified application

Species

Unspecified reactive species

Zi-Jun Sun,Dong-Yuan Chang,Min Chen,Ming-Hui Zhao

Bio-protocol 4: PubMed29094056

2014

Enzymatic Reactions and Detection of C3 Cleavage Fragments.

Applications

Unspecified application

Species

Unspecified reactive species

Claudia Kemper,Martin Kolev

Blood 83:3324-31 PubMed8193368

1994

C3a activates the respiratory burst in human polymorphonuclear neutrophilic leukocytes via pertussis toxin-sensitive G-proteins.

Applications

Unspecified application

Species

Unspecified reactive species

J Elsner,M Oppermann,W Czech,A Kapp

European journal of immunology 24:518-22 PubMed8125125

1994

C3a activates reactive oxygen radical species production and intracellular calcium transients in human eosinophils.

Applications

Unspecified application

Species

Unspecified reactive species

J Elsner,M Oppermann,W Czech,G Dobos,E Schöpf,J Norgauer,A Kapp

Molecular immunology 30:935-40 PubMed8341284

1993

Proteins separated from human IgG molecules.

Applications

Unspecified application

Species

Unspecified reactive species

R Nezlin,A Freywald,M Oppermann

FEBS letters 243:83-7 PubMed2784112

1989

Increase of glucose and lactate output and decrease of flow by human anaphylatoxin C3a but not C5a in perfused rat liver.

Applications

Unspecified application

Species

Unspecified reactive species

G P Püschel,M Oppermann,W Muschol,O Götze,K Jungermann
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com